Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 41,445

Document Document Title
WO/2023/194273A1
The present invention relates to a dosage and administration regimen of anti-C5 antibodies, particularly of the anti-C5 antibody Crovalimab, for use in a method of treating or preventing GBS in a subject. The dosage and treatment regimen...  
WO/2023/196640A1
This disclosure to methods for treating or preventing particular symptoms and disorders which are associated with blood disorders using oxindole derivatives as AMPK activators. Also disclosed are pharmaceutical composition comprising an ...  
WO/2023/195303A1
One of the purposes of the present invention is to provide a hemodialysis agent A having excellent storage stability. The solid hemodialysis agent A contains coated particles having a coating layer containing calcium chloride, and contai...  
WO/2023/194222A1
The present invention covers the use of chymase inhibitors in general and more in particular substituted bicyclically substituted uracils of general formula (I) as described and defined herein, and 3-methylbenzo-[b]thiophene)-2-sulfonami...  
WO/2023/188320A1
The present invention relates to a composition comprising (A) catechin and (B) procyanidin B3, the composition being characterized in that the mass ratio [(A)/(B)] of the content of the component (A) to the content of the component (B) i...  
WO/2023/190665A1
The present invention provides a therapeutic agent, an ameliorative agent, or a preventative agent that have kappa opioid receptor agonist activity and reduced side-effects and are for treating for various diseases relating to kappa opio...  
WO/2023/192848A1
The present invention provides methods for treating reperfusion edema in patients who have suffered a stroke, the methods comprising administering an effective amount of one or more inhibitors of sodium D-glucose cotransporter 2 (SGLT2)....  
WO/2023/192415A1
Provided herein is a method of treating a blood disorder such as sickle cell disease or a β-hemoglobinopathy with an Embryonic Ectoderm Development (EED) inhibitor as described herein.  
WO/2023/185911A1
Use of a pyridinyl sulfonamide phosphate compound or a pharmaceutical composition comprising same in preparing an anti-cerebral edema drug. The pyridinyl sulfonamide phosphate compound can quickly reduce intracranial pressure and is used...  
WO/2023/185852A1
Disclosed are a pharmaceutical composition for injection comprising a cyclic lactam compound (I), a method for preparing the pharmaceutical composition for injection, and use of the pharmaceutical composition in preparing a medicament fo...  
WO/2023/192208A1
Small molecule potentiators that result in the upregulation of an orthogonal receptor with the potential to enhance the efficacy of a biotherapeutic ligand to the receptor, with corticosteroids acting to potentiate RXFP1 binding ligands ...  
WO/2023/190826A1
The present invention relates to a pharmaceutical composition for preventing, suppressing, or treating the symptoms that accompany pseudo-allergic reactions, said pharmaceutical composition comprising, as an active ingredient, a compound...  
WO/2023/185918A1
Provided is an E. coli expressed recombinant human microplasmin (E-μPlm), a production method thereof, a pharmaceutical composition and a kit comprising thereof, an application of the pharmaceutical composition and the kit in treating t...  
WO/2023/190568A1
The present invention provides an osmotic pressure regulating agent that contains allitol or a pharmaceutically acceptable salt thereof. The present invention also provides a transfusion, a peritoneal dialysate, an ophthalmic composition...  
WO/2023/185188A1
A short in vivo half-life and in vivo unstable recombinant microplasmin can be a mutant type and wild type which is expressed in a bacteria host, purified, refolded and purified in case expressed as an insoluble inclusion body. The micro...  
WO/2023/180525A1
Provided is a thermo-regulated process for the recombinant production of an Fc-peptide fusion protein in prokaryotic host cells comprising a single mild temperature shift in the induction phase.  
WO/2023/183667A1
Disclosed herein, are peptides that bind urokinase-type plasminogen activator receptors. The peptides may comprise amino acid sequences of IPPWEAPK (SEQ ID NO: 1), DLAQCQTPTQAAPPTPVSPR (SEQ ID NO: 2), or LHVPLMPAQPAPPK (SEQ ID NO: 3), or...  
WO/2023/180576A1
The invention relates to pharmaceutical matrix tablets for oral administration comprising a bradykinin B2 receptor antagonist having a chemical structure according to Formula (1), or a salt or solvate thereof, wherein R is deuterium or h...  
WO/2023/179274A1
The present invention belongs to the technical field of microorganisms. Disclosed is use of Lactobacillus fermentum in preparing a product for preventing and/or treating thrombus. Also disclosed is an inhibitory effect of a Lactobacillus...  
WO/2023/181563A1
Provided is an anti-adhesive material containing particles, in which the particles comprise a crosslinked product of a gelatin mixture composed of a first gelatin and a second gelatin having such a structure that a hydrocarbon group is i...  
WO/2023/180471A1
Inventors observe that the NButGT treatment increases the O-GlcNAcylation levels of cardiac proteins (p<0.05). Mean arterial pressure decreases 5 hours after ECC procedure compared to the sham group (sham: 95.7 ± 3.7; ECC: 69.8 ± 7.7; ...  
WO/2023/180171A1
The invention provides novel methods of treating methaemoglobinaemia orally in a subject, which methods comprise orally administering to said subject a methylthioninium ("MT") containing salt of the following formula: wherein each of HnA...  
WO/2023/180575A1
The invention relates to solid dispersions for oral administration comprising a bradykinin B2 receptor antagonist having a chemical structure according to Formula (1), or a salt or solvate thereof, wherein R is deuterium or hydrogen: For...  
WO/2023/178465A1
Provided is a method for preparing menstrual blood-derived mesenchymal stem cells, comprising: sieving a menstrual blood sample to obtain a filtrate; performing density gradient centrifugation on the filtrate to obtain a separation solut...  
WO/2023/177952A1
An injectable nanoparticular formulation and method of use thereof for treating non-compressible hemorrhage or internal bleeding has been developed. The formulation includes two interactive components, one a targeting nanoparticle with a...  
WO/2023/176972A1
The present invention relates to a novel therapeutic agent for high-risk myelofibrosis, said agent containing a compound represented by general formula [1] (in the formula, R1, R2, R3, R4, R5, and X are as defined in the description) or ...  
WO/2023/175932A1
The present invention relates to a novel therapeutic agent for high-risk myelofibrosis, said agent containing a compound represented by general formula [1] (in the formula, R1, R2, R3, R4, R5, and X are as defined in the description) or ...  
WO/2023/176709A1
The present disclosure provides: a method for treating a patient who has undergone a pre-transplantation process involved in hematopoietic stem cell transplantation; and a composition for use in said method. The composition according to ...  
WO/2023/174039A1
Disclosed herein are anti-MASP-2 antibodies and antigen-binding fragments, polynucleotides encoding the antibodies and antigen-binding fragments, and pharmaceutical compositions comprising the antibodies and antigen-binding fragments. Us...  
WO/2023/175356A1
The present invention relates to novel compounds suitable for the detection and/or inhibition of coagulation proteases, specifically APC, flla, fXa, and fXla. The compounds have the structural formala (1) or (X) shown below in which R1, ...  
WO/2023/173581A1
A Huatuo Zaizao pill for use in the preparation of a drug for treating aspirin resistance. The Huatuo Zaizao pill has a significant effect on aspirin resistance, and shows good functions in improving blood rheology and blood coagulation ...  
WO/2023/174968A1
The invention relates to the field of pharmaceutical compositions and the treatment and/or prevention of medical conditions comprising thrombosis, or atherosclerosis associated with pathological thrombocyte activation. The invention furt...  
WO/2023/174399A1
The present invention relates to a crystal form of a substituted oxopyridine derivative and to a preparation method therefor. The invention provides a crystal form A of a compound shown in formula (I), as well as a preparation method the...  
WO/2023/174090A1
The present invention relates to a cocrystal of dabigatran etexilate and a method for preparing same, also relates to a pharmaceutical composition comprising the cocrystal, and further relates to use of the cocrystal in preparing an anti...  
WO/2023/176862A1
For example, the present invention provides a new siRNA that has a gene expression suppressing action and/or an RNA interference action with respect to mRNA encoding TfR2. The present invention pertains to: an oligonucleotide that has a ...  
WO/2023/169548A1
Provided is an RNA inhibitor or a pharmaceutically acceptable salt thereof for inhibiting LPA gene expression, the RNA inhibitor comprising a complementary region of an antisense strand, and the complementary region comprising at least 1...  
WO/2023/168743A1
Disclosed is an application of viper venom hemocoagulase in the preparation of a drug for reversing the anticoagulation effect of a blood coagulation factor Xa inhibitor. By means of research on the ability of Slounase, which is a viper ...  
WO/2023/171719A1
The purpose of the present invention is to provide a breakthrough activated protein C that can cure protein C deficiency, a pharmaceutical composition containing the same, etc. The present invention provides a polypeptide, which contains...  
WO/2023/165052A1
Provided is a directionally driven hemostatic microsphere with a puncture function, which comprises hollow pollen and a power system assembled on the surface of the hollow pollen, wherein the surface of the hemostatic microsphere is need...  
WO/2023/165399A1
A Chinese patent medicine preparation for tonifying qi and nourishing blood and a preparation method therefor. The Chinese patent medicine preparation is prepared by the following traditional Chinese medicine raw materials in parts by we...  
WO/2023/164744A1
The present disclosure relates to methods of conditioning a subject and/or depleting a population of cells in the bone marrow of a subject in need of a hematopoietic cell transplantation (HCT) comprising administering an antibody that bi...  
WO/2023/166096A1
The present invention generally relates to the use of bispecific FVIII mimetic antibodies in treatment of haemophilia such as haemophilia A with or without inhibitors and in particular methods for the treatment of the disease such as dos...  
WO/2023/167236A1
The purpose of the present invention is to provide: a composition for ameliorating an unpleasant state related to menstruation, the composition being effective for an unpleasant feeling felt by females from first menstruation to menopaus...  
WO/2023/166094A1
The present invention generally relates to the use of bispecific FVIII mimetic antibodies in treatment of haemophilia such as haemophilia A with or without inhibitors and in particular methods for the treatment of the disease such as dos...  
WO/2023/166097A1
The present invention generally relates to the use of bispecific FVIII mimetic antibodies in treatment of haemophilia such as haemophilia A with or without inhibitors and in particular methods for the treatment of the disease such as dos...  
WO/2023/163170A1
The embolic agent according to the present invention is a copolymer formed from a cationic functional group-containing monomer and an aromatic group-containing monomer, said embolic agent having, as an active ingredient, a copolymer whic...  
WO/2023/164596A1
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the...  
WO/2023/156409A1
Provided herein are antibodies that bind to von Willebrand factor to an epitope positioned at a cysteine knot (CK) domain. Such antibodies are useful for methods of treatment, such methods of treating one or more blood disorders characte...  
WO/2023/156683A1
The present invention relates to an inhibitor of GPVI signaling pathway, in particular an isolated humanized protein binding to human Glycoprotein VI (hGPVI), for treating a GPVI-related condition in a subject in need thereof, in particu...  
WO/2023/158772A1
The present disclosure relates to Danicopan solid state forms, processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.  

Matches 151 - 200 out of 41,445